Abbvie (ABBV) PT Raised to $128 at Mizuho Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech stocks weigh on Wall Street as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- U.S. EV market shows signs of bottoming out: Bernstein
Abbvie (ABBV) PT Raised to $129 at BMO Capital
May 3, 2021 7:31 AM EDTBMO Capital analyst Gary Nachman raised the price target on Abbvie (NYSE: ABBV) to $129.00 (from $127.00) while maintaining an Outperform rating.
The analyst commented, "1Q was high quality with solid top-line beat (mainly from Aesthetics and Immunology) dropping to bottom line, and improved diversification of... More
